Elisabetta Patorno1, Ajinkya Pawar2, Lily G Bessette2, Dae H Kim2,3,4, Chintan Dave2,5, Robert J Glynn2, Medha N Munshi3,6, Sebastian Schneeweiss2, Deborah J Wexler7, Seoyoung C Kim2. 1. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA epatorno@bwh.harvard.edu. 2. Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 3. Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA. 4. Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA. 5. Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ. 6. Joslin Diabetes Center, Harvard Medical School, Boston, MA. 7. Massachusetts General Hospital Diabetes Center and Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: Both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally <65 years old and mostly with cardiovascular disease. We aimed to evaluate the comparative effectiveness and safety of SGLT2i and GLP-1RA among real-world older adults. RESEARCH DESIGN AND METHODS: Using Medicare data (April 2013-December 2016), we identified 90,094 propensity score-matched (1:1) T2D patients ≥66 years old initiating SGLT2i or GLP-1RA. Primary outcomes were major adverse cardiovascular events (MACE) (i.e., myocardial infarction, stroke, or cardiovascular death) and hospitalization for heart failure (HHF). Other outcomes included diabetic ketoacidosis (DKA), genital infections, fractures, lower-limb amputations (LLA), acute kidney injury (AKI), severe urinary tract infections, and overall mortality. We estimated hazard ratios (HRs) and rate differences (RDs) per 1,000 person-years, controlling for 140 baseline covariates. RESULTS: Compared with GLP-1RA, SGLT2i initiators had similar MACE risk (HR 0.98 [95% CI 0.87, 1.10]; RD -0.38 [95% CI -2.48, 1.72]) and reduced HHF risk (HR 0.68 [95% CI 0.57, 0.80]; RD -3.23 [95% CI -4.68, -1.77]), over a median follow-up of ∼6 months. They also had 0.7 more DKA events (RD 0.72 [95% CI 0.02, 1.41]), 0.9 more LLA (RD 0.90 [95% CI 0.10, 1.70]), 57.1 more genital infections (RD 57.08 [95% CI 53.45, 60.70]), and 7.1 fewer AKI events (RD -7.05 [95% CI -10.27, -3.83]) per 1,000 person-years. CONCLUSIONS: Among older adults, those taking SGLT2i had similar MACE risk, decreased HHF risk, and increased risk of DKA, LLA, and genital infections versus those taking GLP-1RA.
OBJECTIVE: Both sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) demonstrated cardiovascular benefits in randomized controlled trials of patients with type 2 diabetes (T2D) generally <65 years old and mostly with cardiovascular disease. We aimed to evaluate the comparative effectiveness and safety of SGLT2i and GLP-1RA among real-world older adults. RESEARCH DESIGN AND METHODS: Using Medicare data (April 2013-December 2016), we identified 90,094 propensity score-matched (1:1) T2D patients ≥66 years old initiating SGLT2i or GLP-1RA. Primary outcomes were major adverse cardiovascular events (MACE) (i.e., myocardial infarction, stroke, or cardiovascular death) and hospitalization for heart failure (HHF). Other outcomes included diabetic ketoacidosis (DKA), genital infections, fractures, lower-limb amputations (LLA), acute kidney injury (AKI), severe urinary tract infections, and overall mortality. We estimated hazard ratios (HRs) and rate differences (RDs) per 1,000 person-years, controlling for 140 baseline covariates. RESULTS: Compared with GLP-1RA, SGLT2i initiators had similar MACE risk (HR 0.98 [95% CI 0.87, 1.10]; RD -0.38 [95% CI -2.48, 1.72]) and reduced HHF risk (HR 0.68 [95% CI 0.57, 0.80]; RD -3.23 [95% CI -4.68, -1.77]), over a median follow-up of ∼6 months. They also had 0.7 more DKA events (RD 0.72 [95% CI 0.02, 1.41]), 0.9 more LLA (RD 0.90 [95% CI 0.10, 1.70]), 57.1 more genital infections (RD 57.08 [95% CI 53.45, 60.70]), and 7.1 fewer AKI events (RD -7.05 [95% CI -10.27, -3.83]) per 1,000 person-years. CONCLUSIONS: Among older adults, those taking SGLT2i had similar MACE risk, decreased HHF risk, and increased risk of DKA, LLA, and genital infections versus those taking GLP-1RA.
Authors: Jane S Saczynski; Susan E Andrade; Leslie R Harrold; Jennifer Tjia; Sarah L Cutrona; Katherine S Dodd; Robert J Goldberg; Jerry H Gurwitz Journal: Pharmacoepidemiol Drug Saf Date: 2012-01 Impact factor: 2.890
Authors: Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll Journal: N Engl J Med Date: 2016-09-15 Impact factor: 91.245
Authors: Peter M Wahl; Keith Rodgers; Sebastian Schneeweiss; Brian F Gage; Javed Butler; Charles Wilmer; Marshall Nash; Gregory Esper; Norman Gitlin; Neal Osborn; Louise J Short; Rhonda L Bohn Journal: Pharmacoepidemiol Drug Saf Date: 2010-06 Impact factor: 2.890
Authors: Thomas A Zelniker; Stephen D Wiviott; Itamar Raz; KyungAh Im; Erica L Goodrich; Remo H M Furtado; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Marc S Sabatine Journal: Circulation Date: 2019-04-23 Impact factor: 29.690
Authors: Michael Fralick; Seoyoung C Kim; Sebastian Schneeweiss; Dae Kim; Donald A Redelmeier; Elisabetta Patorno Journal: Ann Intern Med Date: 2019-01-01 Impact factor: 25.391
Authors: Peter Ueda; Henrik Svanström; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Björn Pasternak Journal: BMJ Date: 2018-11-14
Authors: John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies Journal: Diabetes Care Date: 2019-12-19 Impact factor: 17.152
Authors: X Shao; H Liu; F Hou; Y Bai; Z Cui; Y Lin; X Jiang; P Bai; Y Wang; Y Zhang; C Lu; H Liu; S Zhou; P Yu Journal: J Endocrinol Invest Date: 2022-08-16 Impact factor: 5.467
Authors: Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu Journal: Kidney360 Date: 2022-01-19
Authors: Min Zhuo; Chelsea E Hawley; Julie M Paik; Lily G Bessette; Deborah J Wexler; Dae H Kim; Angela Y Tong; Seoyoung C Kim; Elisabetta Patorno Journal: JAMA Netw Open Date: 2021-10-01